SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 28,900 shares, an increase of 38.3% from the March 15th total of 20,900 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 17,400 shares, the days-to-cover ratio is presently 1.7 days.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $4.64 on Friday. SAB Biotherapeutics has a 1 year low of $4.00 and a 1 year high of $14.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45. The company’s fifty day moving average is $5.00 and its two-hundred day moving average is $3.02.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SABS. Chardan Capital upped their target price on shares of SAB Biotherapeutics from $3.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. HC Wainwright decreased their price objective on shares of SAB Biotherapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of SAB Biotherapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 721,151 shares of the company’s stock worth $2,712,000 after buying an additional 38,179 shares in the last quarter. State Street Corp grew its holdings in SAB Biotherapeutics by 244.2% during the first quarter. State Street Corp now owns 42,341 shares of the company’s stock worth $159,000 after acquiring an additional 30,041 shares during the period. Millennium Management LLC purchased a new position in SAB Biotherapeutics in the second quarter worth $93,000. Citadel Advisors LLC purchased a new position in SAB Biotherapeutics in the third quarter worth $28,000. Finally, HighTower Advisors LLC purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.